Press release
Orphan Drugs Market Japan is Expected to Dominate the Market in Near Future
Orphan drugs are specialized pharmaceutical agents administered for the treatment of rare (orphan) diseases. These diseases have a very low prevalence rate; thus, pharmaceutical companies do not readily invest in these drugs as the returns on investment in orphan drugs are risky as compared to non-orphan drugs. Moreover, multiple clinical trials for drug testing cannot be voluntarily performed due to the small patient population. However, orphan drugs have shown tremendous potential in diagnosis and treatment of cancer; this trend is expected to continue throughout the forecast period.๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
โข Abbvie Inc.
โข Amgen Inc.
โข Amryt Pharma Plc
โข Bristol-Myers Squibb Company
โข F. Hoffmann-La Roche AG
โข GlaxoSmithkline PLC
โข Johnson & Johnson (Janssen Global Services, LLC)
โข Novartis AG (Sandoz)
โข Pfizer, Inc
โข Sanofi S.A.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/204
๐๐๐ ๐ ๐๐๐๐๐๐๐ ๐๐ ๐๐๐ ๐๐๐๐๐
โข Based on disease type, the oncological diseases segment held the largest share in the global orphan drugs market in 2020.
โข Based on region, North America is expected to experience growth at the highest rate, registering a CAGR of 11.0% during the orphan drugs market forecast period.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/204
Favorable government policies and rise in cases of rare diseases boost the orphan drugs market growth. In addition, availability of market exclusivity for orphan drugs developers, and increase in indications of orphan drugs to treat an array of different diseases such as lymphoma, leukemia, myeloma, and others, also boost the growth of the market. However, limited patient pool for clinical trial & product marketing and high treatment costs per patient, restrain the market growth. On the other hand, growth in novel indications designated for known orphan drugs and untapped emerging markets are expected to offer profitable opportunities for the growth of the orphan drugs market during the forecast period.
COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. The global orphan drugs market also declined in 2020 due to factors such as a decline in screening services, reduced access to specialists, treatment interruption, limited operations in most industries, inadequate funding to research & academic institutes, temporary closure of major academic institutes, and disrupted supply chain and challenges. However, the market is anticipated to witness recovery in 2021, and show stable growth for orphan drugs market in the coming future.
The global orphan drugs market is segmented on the basis of disease type, and region. By disease type, it is categorized into oncological diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurological diseases, and other rare diseases that include transplantation diseases, gastrointestinal diseases, dermatologic diseases, perinatal & congenital abnormalities, and others.
๐๐ฒ๐ ๐๐ฒ๐๐ฎ๐ถ๐น๐ฒ๐ฑ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/orphan-drug-market
Contact Us:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter
About Us
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Orphan Drugs Market Japan is Expected to Dominate the Market in Near Future here
News-ID: 2580880 • Views: โฆ
More Releases from Allied Analytics LLP

Heat Meters Market Set to Grow with Rising Demand for Energy Efficiency
According to a new report published by Allied Market Research, the heat meters market size was valued at $1.6 billion in 2022, and is estimated to reach $2.7 billion by 2032, growing at a CAGR of 5.4% from 2023 to 2032.
A heat meter is a device used to measure and quantify the amount of thermal energy (heat) transferred from a heat source to a system or consumer. It accurately measuresโฆ

Heat Pump Market Set for Strong Growth Through 2032
According to a new report published by Allied Market Research, the heat pump market size was valued at $71.2 billion in 2022, and is estimated to reach $201.5 billion by 2032, growing at a CAGR of 11.1% from 2023 to 2032.
A heat pump is a versatile and efficient device that transfers heat from one location to another using a refrigeration cycle. It operates by absorbing heat from a low-temperature sourceโฆ

Energy Efficient Lighting Market Shines Bright with Strong Growth Outlook
According to a new report published by Allied Market Research, the global energy efficient lighting market was valued at $46.2 billion in 2021 and is projected to reach $93.3 billion by 2030, growing at a robust CAGR of 8.1% from 2022 to 2030. This surge reflects a powerful global movement toward greener, smarter, and more cost-effective lighting technologies.
Energy efficient lighting refers to lighting systems and products that use less electricityโฆ

The Future of Energy: How Fuel Cells Are Reshaping Power Generation
According to a new report published by Allied Market Research, titled, "Fuel Cell Market," The fuel cell market size was valued at $3.6 billion in 2020, and is estimated to reach $32.0 billion by 2030, growing at a CAGR of 19.4% from 2021 to 2030.
The fuel cell market has emerged as a transformative force in the global energy landscape, offering a clean, efficient, and sustainable alternative to conventional energy sources.โฆ
More Releases for Orphan
Acquired Orphan Blood Disease Market
Acquired Orphan Blood Disease Market to reach over USD 18.93 billion by the year 2031 - Exclusive Report by InsightAce Analytic
According to a new report by InsightAce Analytic, the "Acquired Orphan Blood Disease Market" in terms of revenue was estimated to be worth $8.65 billion in 2023 and is poised to reach $18.93 billion by 2031, growing at a CAGR of 10.47% from 2024 to 2031.
Get Free Access toโฆ
Orphan Drugs Market Size to Hit $3199.3 Billion by 2028 | Orphan Drugs Industry โฆ
Market Overview:
According to our experience research team, Orphan Drugs Market was valued at USD 112.36 Billion in 2021, and the global Orphan Drugs industry is projected to reach a value of USD 3199.3 Billion by 2028, at a CAGR of 7.4% during the forecast period 2022-2028
Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology, Energy &โฆ
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developedโฆ
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.โฆ
Europe Orphan Drugs Pipeline Analysis
โEurope Orphan Drugs Pipeline Analysisโ by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drugโฆ
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for theโฆ